Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemia
Authors:
- Signe Sparre Beck-NielsenSBSigne Sparre Beck-Nielsen
- Gema AricetaGAGema Ariceta
- Annemieke M BootABAnnemieke M Boot
- Maria Luisa BrandiMaria Luisa Brandi
- Karine BriotKBKarine Briot
- Carmen de Lucas CollantesCCCarmen de Lucas Collantes
- Francesco EmmaFEFrancesco Emma
- Sandro GianniniSandro Giannini
- Dieter HaffnerDHDieter Haffner
- Richard KeenRKRichard Keen
- Elena LevtchenkoELElena Levtchenko
- Ola NilssonONOla Nilsson
Open Access
- 23 June 2026
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (1) , 10-21
Abstract
Objective: X-linked hypophosphataemia (XLH) is a rare genetic disorder characterised by defective bone and tooth mineralisation. Burosumab is a recombinant, human, anti-fibroblast growth factor 23 monoclonal antibody approved for treating XLH. Due to the rarity of the disease, additional safety data for the treatment of XLH with burosumab are required. Design: A post-authorisation safety study analysis of data for paediatric participants from the International X-linked Hypophosphataemia Registry. This study included standard diagnostic and monitoring clinical data at participating centres, regardless of treatment. Methods: This was a second interim analysis performed 5 years after study initiation in the paediatric population. Primary objectives assessed safety outcomes in children and adolescents with XLH. The secondary objective compared safety outcomes with burosumab vs phosphate and/or active vitamin D. Results: In total, 340 participants were treated with ≥1 dose of burosumab, and 91 were treated with phosphate and/or active vitamin D. Overall, 37.4% and 22.0% of participants in the burosumab or phosphate and/or active vitamin D cohorts, respectively, experienced ≥1 adverse event. The proportions of participants with events were similar among children and adolescents. Forty-nine (14.4%) participants reported events possibly/probably related to burosumab. No events led to the withdrawal of burosumab. In both cohorts, no serious adverse events were considered related to treatment, and there were no deaths. Hospitalisations occurred in ∼71% of participants. Hyperphosphataemia, elevated parathyroid hormone, and ectopic mineralisation events were rare. Conclusions: The safety profile of burosumab was consistent with previous studies, and no new safety concerns were reported for children or adolescents.Keywords
Funding Information
- Kyowa Kirin
This publication has 28 references indexed in Scilit:
- Characteristics of oral health of patients with X-linked hypophosphatemia: case reports and literature reviewBDJ Open, 2024
- Epidemiological analysis to identify predictors of X-linked hypophosphatemia (XLH) diagnosis in an Italian pediatric population: the EPIX projectEndocrine, 2024
- Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemiaInternational Journal of Oral Science, 2023
- Prevalence and characteristics of paediatric X-linked hypophosphataemia in Australia and New Zealand: Results from the Australian and the New Zealand Paediatric Surveillance Units surveyBone, 2023
- Burosumab and Dental Abscesses in Children With X‐Linked HypophosphatemiaJBMR Plus, 2022
- Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodCalcified Tissue International, 2019
- Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialThe Lancet, 2019
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary AnalysisJournal of Bone and Mineral Research, 2018
- Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemiaBone, 2017
- A clinician's guide to X-linked hypophosphatemiaJournal of Bone and Mineral Research, 2011